Following is a complete list of oncology studies currently enrolling patients. Click on a link to learn more about it.

Brain Cancer Studies

• Phase I/II Trial of Imatinib Mesylate (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma (NCCTG N0272)

Breast Cancer Studies

• Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (CTSU IBCSG 2402)
• Phase III Randomized Trial of Anastrozole vs. Anastrozole and Fulvestrant as First-Line Therapy for Post-Menopausal Women with Metastatic Breast Cancer (CTSU SWOG S0226)
• Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial (ECOG PACCT-1)
• Phase III Randomized Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (NSABP B-39/RTOG 0413)
• Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in situ Ressected by Lumpectomy
• Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (NSABP B-42)
• Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in situ Resected by Lumpectomy (NSABP B-43)
• Phase III Randomized Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer (ECOG E1105)
• Phase III Double-Blind Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (ECOG E5103)
• Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (CTSU S0307)

Colon Cancer Studies

• Multi-Center, Open-Label, Randomized, Phase II Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as a Second-Line Treatment in Subjects with Metastatic Colorectal Cancer
• Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer (ECOG E4203)
• Phase III Randomized Study Comparing 5-Fluorouracil, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patints with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (ECOG E5202)
• Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin Chemotherapy plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor (NSABP C-10)

Leukemia Studies

• Phase III Randomized Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia
• Phase I/II Study of SKI-606 in Philadelphia Chromosome Positive Leukemias
• Predictors of Adult Leukemia in Minnesota (PALM) Study
• Phase II Randomized Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia (ECOG E1905)
• Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic Leukemia (ECOG 5998)
• Phase II Study of Combination Chemotherapy in Adolescents and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ECOG 10403)
• Phase III Study of the Addition of Gemtuzumab Ozogamicin Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin or No Additional Therapy for Patients Under Age 56 with Previously Untreated De Novo Acute Myeloid Leukemia (CTSU S0106)
• Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia Patients in Second or Subsequent Remission (ECOG E2902)
• Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders (ECOG E3903)
• Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary (SWOG S9910)
• Cytogenic Studies in Leukemia Patients (CTSU S9007)

Lung Cancer Studies

• Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination with Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
• Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer (ECOG E5597)
• Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (ECOG E1505)

Lymphoma Studies

• An Open-Label, Randomized Phase III Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22-Positive, Follicular B-Cell Non-Hodgkin's Lymphoma

Multiple Myeloma Studies

• A Phase I Study of SGN-40 (Anti-hu-CD40 mAb), Lanalidomide (Revlimid®, cc-5013) and Dexamethasone in Patients with Multiple Myeloma
• A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma
• Randomized Phase IIIb Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan and Prednisone (VMP)
• Bone Marker Directed Dosing of ZOMETA® (zoledronic acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma

Myelodysplastic Syndrome Studies

• A Phase I Combination Trial of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) and Lenalidomide (Revlimid®) in Patients with Myelodysplastic Syndromes
• A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
• Phase II Randomized Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia (ECOG E1905)

Neuroendocrine Cancer Studies

• Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (CTSU S0518)

Prostate Cancer Studies

• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Early versus Standard Zolendronic Acid to Prevent Skeletal-Related Events in Men with Prostate Cancer Metastatic to the Bone (CTSU C90202)
• Phase III Study of Docetaxel and Astrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer (CTSU S0421)

Renal Cancer Studies

• Phase III Randomized, Double-Blind Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (ECOG E2805)

Cancer Control Studies

• American Ginseng in Treating Patients with Fatigue Caused by Cancer (NCCTG N07C2)
• Phase III Randomized, Double-Blind, Placebo-Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia (WF98308)